Oncology Reports · 2013 · 46 citations · 15 references
MedicineCell BiologyOncologyCell SignalingChemotherapyMolecular OncologyCancer Cell SignalingChemotherapy ResistanceEpithelial-mesenchymal TransitionEpithelial-to-mesenchymal TransitionOncogenic Signaling PathwaysOvarian CancerEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersOncogenic Signaling NetworksOvarian Cancer ChemotherapyPi3k InhibitorsTherapeutic Drug ResistanceTherapeutic Resistance Mechanisms
Epithelial ovarian cancer is a major cause of mortality among women with gynecological malignancies. Paclitaxel is commonly used for chemotherapy of ovarian cancer, yet its efficacy is limited by chemoresistance. Generally, drug resistance is associated with acquisition of the epithelial-mesenchymal transition (EMT) in cancer. The aim of the present study was to determine whether the EMT is involved in acquired resistance to paclitaxel in A2780 human ovarian cancer cells. Using the paclitaxel-resistant A2780/PTX cell line, we examined the cellular morphology, molecular changes, migration and proliferation consistent with the EMT. Furthermore, we found that inhibition of phosphatidylinositol 3-kinase (PI3K) activity reduced the proliferation and migration and restored their sensitivity to paclitaxel. Our study provides new insights into EMT-like phenotypic changes that are linked to paclitaxel resistance in A2780 cells. We believe that inhibition of the PI3K signaling pathway could provide a novel therapeutic approach to overcome chemoresistance and prevent metastasis during paclitaxel chemotherapy.
15
Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells
Ami N. Shah, Justin M. Summy, Jing Zhang et al. · Annals of Surgical Oncology · 2007 · 433 citations
Medicine, Cell Biology, Oncology +12
Hiroaki Kajiyama, Kiyosumi Shibata, Mikio Terauchi et al. · International Journal of Oncology · 2007 · 409 citations · Full text
Medicine, Oncology, Pharmacology +17